生命科学资讯

Merck-Moderna cancer vaccine sustains 49% melanoma risk reduction at 5 years

Boundless finally gives up on combo treatment of 2 unimpressive cancer drugs

Bristol Myers Squibb taps Microsoft's AI detection network for speedy lung cancer diagnosis

Tanabe Pharma's oral drug scores in ph. 3 rare disease study, though details remain in the dark

Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs

Clinician groups ask court to overturn CDC's childhood vaccine overhaul

Holiday notice

Biggest gainers and losers for Jan. 12-16, 2026

Aspect Bio takes Novo castoff therapies; Takeda trims US jobs

Illumina Gets Reimbursement For FDA-Approved TruSight Oncology Comprehensive Test, Stock Down - Nasdaq

Medicare to cover $2,989.55 Illumina genomic cancer test - Stock Titan

Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology - PR Newswire

GRAIL Inc. - Illumina's Divested Holy Grail (NASDAQ:GRAL) - Seeking Alpha

HSBC Begins Coverage on Agilent Technologies (NYSE:A) - MarketBeat

Teladoc’s mental health arm BetterHelp has quietly expanded the use of AI

2025 ended on high note with a buoyant Q4 for M&A, PIPEs and follow-ons

Sundance Biosciences patents new TYK2 inhibitors for multiple sclerosis

University of Washington discovers HER2-targeting ADCs for cancer

Daewoong Pharmaceutical patents divulge new IRAK-4 inhibitors

Lilly, Takeda targeted by legal strategy usually reserved for the mob